ERBB2 and neoplasm: Given the increasing access to and utilization of tumor tissue and ctDNA NGS in advanced malignancies, we aimed to better understand how ERBB2 copy number gains (CNG) by commercial NGS platforms of tissue or blood predict for HER2-positivity by the ‘gold-standard’ of IHC and FISH assays.